<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02865447</url>
  </required_header>
  <id_info>
    <org_study_id>15-LJH-001</org_study_id>
    <nct_id>NCT02865447</nct_id>
  </id_info>
  <brief_title>Evaluation of Bone Mineral Density Changes After Total Hip Replacement: A Two-Year Clinical and DXA Analysis</brief_title>
  <official_title>A Dual Energy X-ray Absorptiometry (DXA) Evaluation of Bone Density Changes After Hip Replacement. Performance of the PROFEMUR® PRESERVE Hip Stem in Total Hip Arthroplasty, Two-Year Clinical and DXA Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MicroPort Orthopedics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orthopaedic Specialty Clinic of Spokane, PLLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MicroPort Orthopedics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sponsor is conducting this post-market study to evaluate the clinical outcome and femoral&#xD;
      bone mineral density (BMD) changes associated with the PROFEMUR® PRESERVE hip stem when used&#xD;
      as indicated for primary total hip arthroplasty in patients with osteoarthritis of the hip&#xD;
      joint.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 9, 2017</start_date>
  <completion_date type="Actual">August 24, 2020</completion_date>
  <primary_completion_date type="Actual">August 24, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in bone mineral density (BMD), per dual energy x-ray absorptiometry (DXA) imaging, from standard and custom Gruen zones around the femoral stem.</measure>
    <time_frame>1 week Postoperative, 6 weeks, 6 Months, 12 Months, and 24 Months Postoperative</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hip functional outcomes will be assessed using the Harris Hip score.</measure>
    <time_frame>Preoperative, 6 weeks Postoperative, 6 Months, 12 Months, and 24 Months Postoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implant loosening will be assessed by the presence of radiographic lucencies around the femoral stem.</measure>
    <time_frame>6 weeks Postoperative, 6 Months, 12 Months, and 24 Months Postoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implant survivorship of the femoral stem will be calculated.</measure>
    <time_frame>1 week Postoperative, 6 weeks, 6 Months, 12 Months, and 24 Months Postoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complications will be assessed.</measure>
    <time_frame>Preoperative, 6 weeks Postoperative, 6 Months, 12 Months, and 24 Months Postoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hip functional outcomes will be assessed using the Forgotten Joint Score.</measure>
    <time_frame>6 weeks Postoperative, 6 Months, 12 Months, and 24 Months Postoperative</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">25</enrollment>
  <condition>Joint Disease</condition>
  <arm_group>
    <arm_group_label>PRESERVE total hip arthroplasty implant</arm_group_label>
    <description>Subjects to be prospectively implanted with the PROFEMUR PRESERVE total hip arthroplasty implant</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>total hip arthroplasty implant</intervention_name>
    <description>PROFEMUR PRESERVE total hip arthroplasty femoral stem</description>
    <arm_group_label>PRESERVE total hip arthroplasty implant</arm_group_label>
    <other_name>PROFEMUR PRESERVE</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be recruited from the investigator's private orthopedic practice from among&#xD;
        patients who require a total hip arthroplasty.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To be included in the study, subjects must meet all of the following criteria:&#xD;
&#xD;
          -  Subject is minimum age 21 years, maximum age of 80&#xD;
&#xD;
          -  Subject is a candidate for primary THA for osteoarthritis of the hip&#xD;
&#xD;
          -  Subject is able to undergo primary elective THA procedure&#xD;
&#xD;
          -  Subject is willing and able to complete required study visits and assessments&#xD;
&#xD;
          -  Subject is willing to sign the Institutional Review Board/Ethics Committee (IRB/EC)&#xD;
             approved Informed Consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects will be excluded if they meet any of the following criteria:&#xD;
&#xD;
          -  Overt infection;&#xD;
&#xD;
          -  Distant foci of infections (which may cause hematogenous spread to the implant site);&#xD;
&#xD;
          -  Rapid disease progression as manifested by joint destruction or bone absorption&#xD;
             apparent on roentgenogram;&#xD;
&#xD;
          -  Skeletally immature (less than 21 years of age at time of surgery);&#xD;
&#xD;
          -  Inadequate neuromuscular status (e.g., prior paralysis, fusion, and/or inadequate&#xD;
             abductor strength), poor bone stock, poor skin coverage around the joint which would&#xD;
             make the procedure unjustifiable;&#xD;
&#xD;
          -  Neuropathic joints;&#xD;
&#xD;
          -  Known Hepatitis or HIV infection;&#xD;
&#xD;
          -  Neurological or musculoskeletal disease that may adversely affect gait or&#xD;
             weight-bearing&#xD;
&#xD;
          -  Subjects with known osteoporosis of the affected hip&#xD;
&#xD;
          -  Subjects with prior arthroplasty of the affected hip&#xD;
&#xD;
          -  Subjects that are clinically obese (&gt;40 body mass index [BMI])&#xD;
&#xD;
          -  Subjects with femoral dysplasia of the affected hip&#xD;
&#xD;
          -  Subjects with trochanteric osteotomy of the affected hip&#xD;
&#xD;
          -  Subject with inflammatory arthritis of the affected hip&#xD;
&#xD;
          -  Subjects currently taking, or have taken within 12 months of enrollment,&#xD;
             bisphosphonates, parathyroid hormone (PTH), fluoride therapy or strontium ranelate or&#xD;
             patients taking other chronic medications that in the investigator's opinion are known&#xD;
             to affect BMD in a substantial way&#xD;
&#xD;
          -  Subjects with severe medical condition(s) that in the view of the investigator&#xD;
             prohibits participation in the study&#xD;
&#xD;
          -  Subjects currently enrolled in another clinical study which could affect the endpoints&#xD;
             of this protocol&#xD;
&#xD;
          -  Subjects with known substance abuse issues&#xD;
&#xD;
          -  Subjects who are incarcerated or have pending incarceration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Scott, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spokane Joint Replacement Center, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spokane Joint Replacement Center</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 1, 2016</study_first_submitted>
  <study_first_submitted_qc>August 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2016</study_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dual energy x-ray absorptiometry</keyword>
  <keyword>DEXA</keyword>
  <keyword>DXA</keyword>
  <keyword>total hip arthroplasty</keyword>
  <keyword>PROFEMUR</keyword>
  <keyword>PRESERVE</keyword>
  <keyword>bone mineral density</keyword>
  <keyword>BMD</keyword>
  <keyword>osteoarthritis</keyword>
  <keyword>THA</keyword>
  <keyword>musculoskeletal disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Joint Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

